Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
CCTG HN13 clinical trial has successfully been awarded $1,602,675 in the Spring 2023 CIHR funding competition to investigate improving head and neck tumour and symptom control in patients who are unable to tolerate curative radiotherapy.
GCAR1 is a Phase I feasibility and safety study of Chimeric Antigen Receptor (CAR) T-cell therapy for patients with relapsed/refractory GPNMB-Expressing solid tumors.
The CCTG MY13 study receives $3,056,172 over 8 years to investigate time-limited versus continuous Daratumumab treatment for older people with multiple myeloma.
The CEC5 (ALLIANCE A221208) Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases trial has permanently closed.
Please save the date for the 2024 Annual Spring Meeting of Participants which will be held at the Chelsea Hotel from Friday, May 3 to Sunday, May, 5.
The spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
